Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Tunis Med ; 96(5): 269-272, 2018 May.
Artigo em Inglês | MEDLINE | ID: mdl-30430499

RESUMO

AIM: To report the epidemiologic, clinical features, treatment modalities and prognosis of primary bone lymphomas (PBL) within a retrospective Tunisian series. METHODS: We collected cases of histologically confirmed PBL in 3 medical oncology departments from northern and central Tunisia andwe analyzed their characteristics. RESULTS: From January 1990 to July 2014, we collected 32 patients with histologically proven PBL, having a median age of 53 years. They affected mainly the long bones and diagnosed at early stages. 91% of the PBL were large cell B lymphoma. All patients received CHOP or CHOP-likeChemotherapy (CT), associated to Rituximab in the last 9 cases, with 14/32 patients received loco-regional radiotherapy and one patient had a resection-reconstruction surgery. We observed 90% of objective responses after primary CT.With a median follow-up of 38.5 months (1 to 192), the 5-year overall survival OS rate was 63%.18 patients relapsed and 14 remain alive in complete remission. CONCLUSION: PBL remains a rare disease lately diagnosed in Tunisia. However, most of the patients had early stages tumors. Furthermore, the efficacy of CT and introduction of Rituximab leads to a high rate of complete/objective responses, improving the survival rate.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Ósseas/patologia , Linfoma de Células B/patologia , Linfoma/patologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Neoplasias Ósseas/terapia , Criança , Ciclofosfamida/administração & dosagem , Ciclofosfamida/uso terapêutico , Doxorrubicina/administração & dosagem , Doxorrubicina/uso terapêutico , Feminino , Seguimentos , Humanos , Linfoma/terapia , Linfoma de Células B/terapia , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Prednisolona/administração & dosagem , Prednisolona/uso terapêutico , Prognóstico , Indução de Remissão , Estudos Retrospectivos , Rituximab/administração & dosagem , Taxa de Sobrevida , Resultado do Tratamento , Tunísia , Vincristina/administração & dosagem , Vincristina/uso terapêutico , Adulto Jovem
2.
Phys Rev Lett ; 113(18): 181301, 2014 Oct 31.
Artigo em Inglês | MEDLINE | ID: mdl-25396358

RESUMO

We show that a general late-time interaction between cold dark matter and vacuum energy is favored by current cosmological data sets. We characterize the strength of the coupling by a dimensionless parameter q(V) that is free to take different values in four redshift bins from the primordial epoch up to today. This interacting scenario is in agreement with measurements of cosmic microwave background temperature anisotropies from the Planck satellite, supernovae Ia from Union 2.1 and redshift space distortions from a number of surveys, as well as with combinations of these different data sets. Our analysis of the 4-bin interaction shows that a nonzero interaction is likely at late times. We then focus on the case q(V)≠0 in a single low-redshift bin, obtaining a nested one parameter extension of the standard ΛCDM model. We study the Bayesian evidence, with respect to ΛCDM, of this late-time interaction model, finding moderate evidence for an interaction starting at z=0.9, dependent upon the prior range chosen for the interaction strength parameter q(V). For this case the null interaction (q(V)=0, i.e., ΛCDM) is excluded at 99% C.L.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA